Dishman Carbogen Amics (NSE:DCAL) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:DCAL Dishman Carbogen Amics Ltd NSE:DCAL
69 GF Score
Price ₹170.52
GF Value ₹236.83
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Dishman Carbogen Amics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dishman Carbogen Amics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹ Mil. Dishman Carbogen Amics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹ Mil. Dishman Carbogen Amics's annualized EBITDA for the quarter that ended in Jun. 2026 was ₹306 Mil. Dishman Carbogen Amics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Dishman Carbogen Amics's Debt-to-EBITDA or its related term are showing as below:

NSE:DCAL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.76   Med: 5.15   Max: 7.66
Current: 4.98

During the past 13 years, the highest Debt-to-EBITDA Ratio of Dishman Carbogen Amics was 7.66. The lowest was 1.76. And the median was 5.15.

NSE:DCAL's Debt-to-EBITDA is ranked worse than
76.64% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs NSE:DCAL: 4.98

Dishman Carbogen Amics  (NSE:DCAL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Dishman Carbogen Amics Debt-to-EBITDA Related Terms

Dishman Carbogen Amics Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Dishman Carbogen Amics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dishman Carbogen Amics Debt-to-EBITDA Chart

Dishman Carbogen Amics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dishman Carbogen Amics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NSE:DCAL vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Dishman Carbogen Amics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dishman Carbogen Amics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dishman Carbogen Amics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dishman Carbogen Amics's Debt-to-EBITDA falls into.


NSE:DCAL
69GF Score
Dishman Carbogen Amics Ltd NSE:DCAL
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dishman Carbogen Amics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Dishman Carbogen Amics's Debt-to-EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(13179.1 + 17581.5) / 6177.7
=4.98

Dishman Carbogen Amics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 306.2
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Dishman Carbogen Amics (NSE:DCAL) Overvalued in 2026?

Based on GuruFocus' analysis, Dishman Carbogen Amics stock appears to be undervalued. The current stock price of ₹170.52 is trading 28% below its estimated GF Value™ of ₹236.83. GuruFocus considers Dishman Carbogen Amics to be Modestly Undervalued.

Key valuation signals for NSE:DCAL:

  • Debt-to-EBITDA:
  • GF Value™: ₹236.83 vs. price of ₹170.52 (28% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the NSE:DCAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dishman Carbogen Amics Business Description

Other Exchanges 540701:India
Address Iscon-Bopal Road, Dishman Corporate House, Ambli, Ahmedabad, GJ, IND, 380 058
Dishman Carbogen Amics Ltd is a biotechnology company that provides contract research and manufacturing services for pharmaceutical companies. It manufactures bulk drugs, specialty chemicals, and outsourced goods. Additionally, the company produces vitamins, such as vitamin D2 and vitamin D3, reagents, antiseptics and disinfectants, transfer catalysts, personal-care ingredients, pharma intermediates, and ammonium and phosphonium high-purity solid Quats. The business generates the vast majority of its revenue in India.
69GF Score

Get the complete analysis for NSE:DCAL

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹170.52
Price
₹236.83
GF Value